Guardian Pharmacy Services (GRDN) Projected to Release Quarterly Earnings on Thursday

Guardian Pharmacy Services (NYSE:GRDN) will likely be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Guardian Pharmacy Services to post earnings of $0.2617 per share and revenue of $340.4490 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.05. The company had revenue of $336.60 million during the quarter, compared to analyst estimates of $329.89 million. Guardian Pharmacy Services had a net margin of 3.64% and a return on equity of 30.72%. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.22 EPS. On average, analysts expect Guardian Pharmacy Services to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Guardian Pharmacy Services Price Performance

Shares of GRDN traded up $0.20 during mid-day trading on Tuesday, hitting $41.01. The company’s stock had a trading volume of 59,009 shares, compared to its average volume of 387,276. The firm has a 50-day moving average price of $40.76 and a 200 day moving average price of $36.81. Guardian Pharmacy Services has a fifty-two week low of $19.30 and a fifty-two week high of $44.00. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 49.48, a PEG ratio of 2.59 and a beta of 0.11.

Hedge Funds Weigh In On Guardian Pharmacy Services

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Police & Firemen s Retirement System of New Jersey grew its holdings in shares of Guardian Pharmacy Services by 20.4% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company’s stock valued at $183,000 after acquiring an additional 1,028 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Guardian Pharmacy Services during the fourth quarter worth $230,000. Intech Investment Management LLC acquired a new stake in Guardian Pharmacy Services during the fourth quarter valued at $223,000. Schonfeld Strategic Advisors LLC acquired a new stake in Guardian Pharmacy Services during the third quarter valued at $211,000. Finally, JPMorgan Chase & Co. grew its stake in Guardian Pharmacy Services by 31.1% in the third quarter. JPMorgan Chase & Co. now owns 7,899 shares of the company’s stock valued at $207,000 after purchasing an additional 1,872 shares in the last quarter.

Analyst Upgrades and Downgrades

GRDN has been the topic of several research reports. Truist Financial upped their price target on Guardian Pharmacy Services from $43.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Bank of America raised their price objective on Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Zacks Research cut Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Weiss Ratings lowered Guardian Pharmacy Services from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, Oppenheimer boosted their target price on Guardian Pharmacy Services from $38.00 to $43.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.83.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.